Deborah Dukovic

1.0k total citations · 1 hit paper
17 papers, 755 citations indexed

About

Deborah Dukovic is a scholar working on Pathology and Forensic Medicine, Immunology and Rheumatology. According to data from OpenAlex, Deborah Dukovic has authored 17 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Immunology and 4 papers in Rheumatology. Recurrent topics in Deborah Dukovic's work include Multiple Sclerosis Research Studies (6 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Urticaria and Related Conditions (3 papers). Deborah Dukovic is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Urticaria and Related Conditions (3 papers). Deborah Dukovic collaborates with scholars based in United States, France and Canada. Deborah Dukovic's co-authors include Philippe Truffinet, Ludwig Kappos, Tomas Olsson, Jerry S. Wolinsky, Mark Freedman, Aaron Miller, Paul O’Connor, Armin Grau, Werner Hacke and Christoph Lichy and has published in prestigious journals such as Neurology, Stroke and The Lancet Neurology.

In The Last Decade

Deborah Dukovic

17 papers receiving 728 citations

Hit Papers

Oral teriflunomide for patients with relapsing multiple s... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
    2014 402 citations Christian Confavreux, Paul O’Connor et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Dukovic United States 6 434 210 200 163 139 17 755
Xiaojun You United States 19 647 1.5× 216 1.0× 236 1.2× 58 0.4× 250 1.8× 52 846
Orla Tuohy United Kingdom 7 440 1.0× 200 1.0× 145 0.7× 53 0.3× 101 0.7× 8 730
Hyon‐Jo Kwon South Korea 14 101 0.2× 71 0.3× 412 2.1× 367 2.3× 236 1.7× 65 1.1k
Patrick J. Oliverio United States 11 143 0.3× 58 0.3× 132 0.7× 91 0.6× 363 2.6× 15 896
G. Castellino Italy 17 185 0.4× 33 0.2× 165 0.8× 64 0.4× 623 4.5× 32 934
Michio Ozeki Japan 17 166 0.4× 299 1.4× 238 1.2× 31 0.2× 58 0.4× 76 924
Rosario Foti Italy 16 133 0.3× 72 0.3× 64 0.3× 73 0.4× 427 3.1× 93 986
A. M�ller Germany 7 239 0.6× 206 1.0× 74 0.4× 114 0.7× 26 0.2× 16 564
Flavia Del Porto Italy 16 78 0.2× 57 0.3× 106 0.5× 69 0.4× 354 2.5× 44 1.0k
Jamal Mikdashi United States 11 147 0.3× 40 0.2× 167 0.8× 56 0.3× 572 4.1× 28 736

Countries citing papers authored by Deborah Dukovic

Since Specialization
Citations

This map shows the geographic impact of Deborah Dukovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Dukovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Dukovic more than expected).

Fields of papers citing papers by Deborah Dukovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Dukovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Dukovic. The network helps show where Deborah Dukovic may publish in the future.

Co-authorship network of co-authors of Deborah Dukovic

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Dukovic. A scholar is included among the top collaborators of Deborah Dukovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Dukovic. Deborah Dukovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Oh, Jiwon, Robert J. Fox, Douglas L. Arnold, et al.. (2025). Tolebrutinib Phase 2b Long-Term Extension Study. PubMed. 1(3). 1 indexed citations
2.
Syed, Sana, Christopher LaGanke, William Honeycutt, et al.. (2021). Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study (2260). Neurology. 96(15_supplement). 5 indexed citations
3.
Quan, Hui, Juan Zhang, Dongli Zhou, & Deborah Dukovic. (2017). Estimation of Standard Deviation for a Log-Transformed Variable Based on Summary Statistics in the Original Scale. Statistics in Biopharmaceutical Research. 10(1). 30–38. 1 indexed citations
4.
Leist, Thomas, Mark Freedman, Ludwig Kappos, et al.. (2015). Pooled Safety Analyses from Teriflunomide Clinical Studies (P7.268). Neurology. 84(14_supplement). 3 indexed citations
5.
Comi, Cristoforo, Mark Freedman, Ludwig Kappos, et al.. (2015). Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Multiple Sclerosis and Related Disorders. 5. 97–104. 61 indexed citations
6.
Kremenchutzky, Marcelo, Mark Freedman, Amit Bar‐Or, et al.. (2015). 12-Year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study (P7.223). Neurology. 84(14_supplement). 2 indexed citations
7.
Sèze, J. de, Tomas Olsson, Anna Członkowska, et al.. (2015). Safety and Efficacy of Teriflunomide in Patients Switching from Subcutaneous Interferon Beta-1a (P7.275). Neurology. 84(14_supplement). 1 indexed citations
8.
Olsson, Tomas, Gıancarlo Comı, Mark Freedman, et al.. (2014). Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses of Two Phase 3 Placebo-Controlled Trials (P3.164). Neurology. 82(10_supplement). 1 indexed citations
9.
Confavreux, Christian, Paul O’Connor, Gıancarlo Comı, et al.. (2014). Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. 13(3). 247–256. 402 indexed citations breakdown →
10.
Leist, Thomas, Mark Freedman, Myriam Bénamor, et al.. (2014). Pooled Safety Data From Four Placebo-Controlled Teriflunomide Studies (P2.203). Neurology. 82(10_supplement). 2 indexed citations
11.
Jumah, Mohammed Al, et al.. (2014). Long-term clinical and magnetic resonance imaging outcomes from patients treated with teriflunomide: Results from a phase 2 extension study. Multiple Sclerosis and Related Disorders. 3(6). 755–756. 1 indexed citations
12.
Wolinsky, Jerry S., Deborah Dukovic, Philippe Truffinet, & Ludwig Kappos. (2014). Estimating the Onset of Efficacy With Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (P7.214). Neurology. 82(10_supplement). 1 indexed citations
13.
Freedman, Mark, Jerry S. Wolinsky, Gıancarlo Comı, et al.. (2014). Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: Update of the TEMSO Extension Trial (P3.150). Neurology. 82(10_supplement). 3 indexed citations
14.
Freedman, M. S., P. O’Connor, J. S. Wolinsky, et al.. (2012). Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007). Neurology. 78(Meeting Abstracts 1). PD5.007–PD5.007. 12 indexed citations
15.
Grau, Armin, Deborah Dukovic, Florian Buggle, et al.. (2004). Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events. Stroke. 35(5). 1147–1152. 245 indexed citations
16.
Morris, T. W., Deborah Dukovic, & Edward D. Pagani. (1995). Cardiac hemodynamic effects of iodixanol, iopamidol, and ioxaglate following left coronary injections in anesthetized dogs. Academic Radiology. 2(1). 33–37. 5 indexed citations
17.
Morris, T. W., Deborah Dukovic, & Edward D. Pagani. (1994). The Effects of Coronary Injections of Iodixanol, Iopamidol, and Ioxaglate on Contractility and Electrophysiology. Investigative Radiology. 29. S99–S101. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaojun You Breakdown of academic impact, for papers by Orla Tuohy Breakdown of academic impact, for papers by Hyon‐Jo Kwon Breakdown of academic impact, for papers by Patrick J. Oliverio Breakdown of academic impact, for papers by G. Castellino Breakdown of academic impact, for papers by Michio Ozeki Breakdown of academic impact, for papers by Rosario Foti Breakdown of academic impact, for papers by A. M�ller Breakdown of academic impact, for papers by Flavia Del Porto Breakdown of academic impact, for papers by Jamal Mikdashi
Rankless by CCL
2026